Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Methods: Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group); untreated, CBI model rats (CBI group); and CBI rats treated daily with 4 mg/kg mirodenafil (CBI+mirodenafil group). The CBI and CBI+mirodenafil groups underwent endothelial injury to the iliac arteries and were fed a 2% cholesterol diet after injury. Four weeks after surgery, the CBI+mirodenafil group started daily treatment with mirodenafil for four weeks. Eight weeks after surgery, continuous in vivo cystometry and in vitro organ bath studies of detrusor muscle strips were performed. Results: In vivo cystometry revealed that the rats in the CBI group had a significantly higher micturition frequency, lower bladder capacity, and lower compliance than the rats in the control and CBI+mirodenafil groups. The detrusor muscle strip study showed that the magnitude of the carbachol-induced contractile response was significantly lower in the CBI group compared to either the control or CBI+mirodenafil group. Addition of daily mirodenafil after induction of CBI decreased the contractile response, compared to untreated CBI rats. CBI induced submucosal fibrosis and degenerative changes in bladder walls, which was reversed by the addition of mirodenafil. Conclusions: Daily treatment with mirodenafil showed protective effects against bladder dysfunction resulting from CBI in rats.

Original languageEnglish
Pages (from-to)19-26
Number of pages8
JournalInternational Neurourology Journal
Volume19
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Urinary Bladder
Ischemia
mirodenafil
Muscles
Urination
Iliac Artery
Wounds and Injuries
Carbachol
Baths
Compliance
Sprague Dawley Rats

Keywords

  • Ischemia
  • Phosphodiesterase 5 Inhibitors
  • Urinary bladder

ASJC Scopus subject areas

  • Clinical Neurology
  • Urology
  • Neurology

Cite this

@article{a47615390aa0484ca268554cef79f89b,
title = "Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats",
abstract = "Purpose: To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Methods: Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group); untreated, CBI model rats (CBI group); and CBI rats treated daily with 4 mg/kg mirodenafil (CBI+mirodenafil group). The CBI and CBI+mirodenafil groups underwent endothelial injury to the iliac arteries and were fed a 2{\%} cholesterol diet after injury. Four weeks after surgery, the CBI+mirodenafil group started daily treatment with mirodenafil for four weeks. Eight weeks after surgery, continuous in vivo cystometry and in vitro organ bath studies of detrusor muscle strips were performed. Results: In vivo cystometry revealed that the rats in the CBI group had a significantly higher micturition frequency, lower bladder capacity, and lower compliance than the rats in the control and CBI+mirodenafil groups. The detrusor muscle strip study showed that the magnitude of the carbachol-induced contractile response was significantly lower in the CBI group compared to either the control or CBI+mirodenafil group. Addition of daily mirodenafil after induction of CBI decreased the contractile response, compared to untreated CBI rats. CBI induced submucosal fibrosis and degenerative changes in bladder walls, which was reversed by the addition of mirodenafil. Conclusions: Daily treatment with mirodenafil showed protective effects against bladder dysfunction resulting from CBI in rats.",
keywords = "Ischemia, Phosphodiesterase 5 Inhibitors, Urinary bladder",
author = "Hoon Choi and Bae, {Jae Hyun} and Shim, {Ji Sung} and Park, {Jae Young} and Moon, {Du Geon} and Lee, {Jeong Gu}",
year = "2015",
month = "1",
day = "1",
doi = "10.5213/inj.2015.19.1.19",
language = "English",
volume = "19",
pages = "19--26",
journal = "International Neurourology Journal",
issn = "2093-4777",
publisher = "Korean Association of Medical Journal Edirors",
number = "1",

}

TY - JOUR

T1 - Mirodenafil prevents bladder dysfunction induced by chronic bladder ischemia in rats

AU - Choi, Hoon

AU - Bae, Jae Hyun

AU - Shim, Ji Sung

AU - Park, Jae Young

AU - Moon, Du Geon

AU - Lee, Jeong Gu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Methods: Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group); untreated, CBI model rats (CBI group); and CBI rats treated daily with 4 mg/kg mirodenafil (CBI+mirodenafil group). The CBI and CBI+mirodenafil groups underwent endothelial injury to the iliac arteries and were fed a 2% cholesterol diet after injury. Four weeks after surgery, the CBI+mirodenafil group started daily treatment with mirodenafil for four weeks. Eight weeks after surgery, continuous in vivo cystometry and in vitro organ bath studies of detrusor muscle strips were performed. Results: In vivo cystometry revealed that the rats in the CBI group had a significantly higher micturition frequency, lower bladder capacity, and lower compliance than the rats in the control and CBI+mirodenafil groups. The detrusor muscle strip study showed that the magnitude of the carbachol-induced contractile response was significantly lower in the CBI group compared to either the control or CBI+mirodenafil group. Addition of daily mirodenafil after induction of CBI decreased the contractile response, compared to untreated CBI rats. CBI induced submucosal fibrosis and degenerative changes in bladder walls, which was reversed by the addition of mirodenafil. Conclusions: Daily treatment with mirodenafil showed protective effects against bladder dysfunction resulting from CBI in rats.

AB - Purpose: To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Methods: Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group); untreated, CBI model rats (CBI group); and CBI rats treated daily with 4 mg/kg mirodenafil (CBI+mirodenafil group). The CBI and CBI+mirodenafil groups underwent endothelial injury to the iliac arteries and were fed a 2% cholesterol diet after injury. Four weeks after surgery, the CBI+mirodenafil group started daily treatment with mirodenafil for four weeks. Eight weeks after surgery, continuous in vivo cystometry and in vitro organ bath studies of detrusor muscle strips were performed. Results: In vivo cystometry revealed that the rats in the CBI group had a significantly higher micturition frequency, lower bladder capacity, and lower compliance than the rats in the control and CBI+mirodenafil groups. The detrusor muscle strip study showed that the magnitude of the carbachol-induced contractile response was significantly lower in the CBI group compared to either the control or CBI+mirodenafil group. Addition of daily mirodenafil after induction of CBI decreased the contractile response, compared to untreated CBI rats. CBI induced submucosal fibrosis and degenerative changes in bladder walls, which was reversed by the addition of mirodenafil. Conclusions: Daily treatment with mirodenafil showed protective effects against bladder dysfunction resulting from CBI in rats.

KW - Ischemia

KW - Phosphodiesterase 5 Inhibitors

KW - Urinary bladder

UR - http://www.scopus.com/inward/record.url?scp=84929334537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929334537&partnerID=8YFLogxK

U2 - 10.5213/inj.2015.19.1.19

DO - 10.5213/inj.2015.19.1.19

M3 - Article

AN - SCOPUS:84929334537

VL - 19

SP - 19

EP - 26

JO - International Neurourology Journal

JF - International Neurourology Journal

SN - 2093-4777

IS - 1

ER -